Frequent Epigenetic Silencing of the p16 Gene in Non‐small Cell Lung Cancers of Tobacco Smokers

Epidemiological studies have demonstrated a causal link between tobacco smoking and lung cancer. We investigated the association between inactivation of the p16 gene and tobacco smoking in 51 non‐small cell lung cancers (NSCLCs). Aberrations of the p16 gene were studied by PCR single‐strand conformation polymorphism analysis, followed by direct sequencing, microsatellite analysis, methylation‐specific PCR, and immunohistochemistry. Mutations were detected in 3.9% (2/51) of the tumors; the tumors carrying mutations were from smokers. The incidences of loss of heterozygosity, homozygous deletion, and promoter methylation in 37 smokers vs. 14 non‐smokers were; 45.9% vs. 28.6%, 16.2% vs. 7.1%, and 35.1% vs. 7.1%, respectively. Among these, only the association between promoter methylation and tobacco smoking was statistically significant (P<0.05). Therefore, epigenetic aberration is considered to be a major causative event in p16 silencing by tobacco smoking. Loss of p16 protein expression was apparent in 49% (25/51) of the tumors, and was associated with tobacco smoking (P<0.05) and with histological type (P<0.05). These findings suggest that tobacco smoking leads to inactivation of the p16 gene mainly through the epigenetic mechanism, ultimately increasing the risk of NSCLC, especially the squamous cell histological type.

[1]  F. Gilliland,et al.  Aberrant promoter methylation in bronchial epithelium and sputum from current and former smokers. , 2002, Cancer research.

[2]  John K. Wiencke,et al.  p16INK4a and Histology-specific Methylation of CpG Islands by Exposure to Tobacco Smoke in Non-Small Cell Lung Cancer , 2001 .

[3]  J. Herman,et al.  Increased loss of chromosome 9p21 but not p16 inactivation in primary non-small cell lung cancer from smokers. , 2001, Cancer research.

[4]  E. Mark,et al.  p16(INK4a) and histology-specific methylation of CpG islands by exposure to tobacco smoke in non-small cell lung cancer. , 2001, Cancer research.

[5]  J. Minna,et al.  Aberrant promoter methylation of multiple genes in non-small cell lung cancers. , 2001, Cancer research.

[6]  T. Lee,et al.  Molecular and genetic aspects of lung cancer. , 2000, American journal of respiratory and critical care medicine.

[7]  V. Gorgoulis,et al.  Expression of p16INK4A and alterations of the 9p21‐23 chromosome region in non‐small‐cell lung carcinomas: Relationship with tumor growth parameters and ploidy status , 2000, International journal of cancer.

[8]  D. Niewoehner,et al.  Rb and @16@4a Expression in Resected Non-Small Cell Lung Tumors' , 2000 .

[9]  E. Mark,et al.  Implications and prognostic value of K-ras mutation for early-stage lung cancer in women. , 1999, Journal of the National Cancer Institute.

[10]  J. Herman,et al.  Inactivation of the INK4A/ARF locus frequently coexists with TP53 mutations in non-small cell lung cancer , 1999, Oncogene.

[11]  J. McLaughlin,et al.  Meta-analyses of p53 tumor suppressor gene alterations and clinicopathological features in resected lung cancers. , 1999, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[12]  T. Halazonetis,et al.  Alterations of the p16-pRb pathway and the chromosome locus 9p21-22 in non-small-cell lung carcinomas: relationship with p53 and MDM2 protein expression. , 1998, The American journal of pathology.

[13]  E Gabrielson,et al.  Aberrant methylation of p16(INK4a) is an early event in lung cancer and a potential biomarker for early diagnosis. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[14]  T. Nakajima,et al.  Correlation between methylation status of the p16/CDKN2 gene and the expression of p16 and Rb proteins in primary non‐small cell lung cancers , 1998, International journal of cancer.

[15]  V. Gouyer,et al.  Mechanisms of p16INK4A inactivation in non small-cell lung cancers , 1998, Oncogene.

[16]  J. Jen,et al.  Detailed deletion mapping at chromosome 9p21 in non‐small cell lung cancer by microsatellite analysis and fluorescence in situ hybridization , 1997, International journal of cancer.

[17]  S. Hirohashi,et al.  DNA hypermethylation at the D17S5 locus in non-small cell lung cancers: its association with smoking history. , 1997, Cancer research.

[18]  A. Marchetti,et al.  Association between cigarette smoking and FHIT gene alterations in lung cancer. , 1997, Cancer research.

[19]  J. Herman,et al.  Frequent aberrant methylation of p16INK4a in primary rat lung tumors , 1997, Molecular and cellular biology.

[20]  A. Giordano,et al.  Prognostic value of p53 in non-small cell lung cancer: relationship with proliferating cell nuclear antigen and cigarette smoking. , 1997, Human pathology.

[21]  M. Tang,et al.  Preferential Formation of Benzo[a]pyrene Adducts at Lung Cancer Mutational Hotspots in P53 , 1996, Science.

[22]  J. Herman,et al.  Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[23]  J. Bartek,et al.  High frequency of p16 (CDKN2/MTS-1/INK4A) inactivation in head and neck squamous cell carcinoma. , 1996, Cancer research.

[24]  D. Niewoehner,et al.  Rb and p16INK4a expression in resected non-small cell lung tumors. , 1996, Cancer research.

[25]  S. Baylin,et al.  Increased cytosine DNA-methyltransferase activity is target-cell-specific and an early event in lung cancer. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[26]  Carl W. Miller,et al.  Alterations of CDKN2 (p16) in non‐small cell lung cancer , 1995, Genes, chromosomes & cancer.

[27]  Kathleen R. Cho,et al.  Frequency of homozygous deletion at p16/CDKN2 in primary human tumours , 1995, Nature Genetics.

[28]  J. Herman,et al.  5′ CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers , 1995, Nature Medicine.

[29]  R. Weinberg,et al.  The retinoblastoma protein and cell cycle control , 1995, Cell.

[30]  Y. W. Lee,et al.  Carcinogenic nickel silences gene expression by chromatin condensation and DNA methylation: a new model for epigenetic carcinogens , 1995, Molecular and cellular biology.

[31]  G. Tamura,et al.  Loss of Heterozygosity on the Short Arm of Chromosome 9 without p16 Gene Mutation in Gastric Carcinomas , 1995, Japanese journal of cancer research : Gann.

[32]  G. Hannon,et al.  Mutations in the p16INK4/MTS1/CDKN2, p15INK4B/MTS2, and p18 genes in primary and metastatic lung cancer. , 1995, Cancer research.

[33]  C. Sherr.  G1 phase progression: Cycling on cue , 1994, Cell.

[34]  C. Harris,et al.  Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. , 1994, Cancer research.

[35]  D. Sidransky,et al.  Rates of p16 (MTS1) mutations in primary tumors with 9p loss. , 1994, Science.

[36]  D. Carson,et al.  Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers , 1994, Nature.

[37]  M. Skolnick,et al.  A cell cycle regulator potentially involved in genesis of many tumor types. , 1994, Science.

[38]  Yoshiro,et al.  Genesis of squamous cell lung carcinoma. Sequential changes of proliferation, DNA ploidy, and p53 expression. , 1994, The American journal of pathology.

[39]  G. Hannon,et al.  A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4 , 1993, Nature.

[40]  T. Nakayama,et al.  Cigarette smoke induces DNA single-strand breaks in human cells , 1985, Nature.